Drug
Adebrelimab clinical trials
Also written SHR-1316 and HTI-1088.
- studies test it
- 180
- open now
- 163
- in phase 3
- 15
- first study started
- 2017
Keep track of what changes. Save the adebrelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
180 studies that test it; most in 2024 (69)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 16 |
| 2024 | 69 |
| 2025 | 40 |
| 2026 | 40 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 30
- Phase 2
- 150
- Phase 3
- 15
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 35 · Other 145
Fudan University (16) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (12) · Tianjin Medical University Cancer Institute and Hospital (10) · Jiangsu HengRui Medicine Co., Ltd. (8) · Sun Yat-sen University (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Shanghai Hengrui Pharmaceutical Co., Ltd. (6) · Peking University Cancer Hospital & Institute (5)
Often tested with
Tested in the same studies.
Apatinib (27) · Paclitaxel (19) · Trastuzumab rezetecan (17) · Albumin-Bound Paclitaxel (12) · Bevacizumab (10) · Carboplatin (8) · Cisplatin (8) · Oxaliplatin (7)
Studies
Open first, then newest update. How each study uses adebrelimab is read from its arms, and is right about nine times in ten.
Testing it · 180
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625Written as Adebrelimab Injection
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as SHR-1316
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT07824882Written as Adebrelimab Injection
- Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCNot yet recruitingPhase 2Ruijin HospitalNCT07890636Written as Adebrelimab
- Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerRecruitingPhase 1Second Xiangya Hospital of Central South UniversityNCT07886047Written as Adebrelimab
- A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLCRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07798947Written as SHR-1316
- Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tongji HospitalNCT07865611Written as Adebrelimab
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07863167Written as adebrelimab + SHR-A2009
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Adebrelimab
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07691762Written as SHR-8068 + Adebrelimab + Bevacizumab
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664Written as Adebrelimab
- Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNot yet recruitingPhase 2Ming ChenNCT07836543Written as Adebrelimab
- Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerRecruitingPhase 2Jiangmen Central HospitalNCT07583550Written as Adebrelimab
- Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic CancerNot yet recruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07827053Written as Adebrelimab (PD-L1 inhibitor)
- A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07822542Written as Adebrelimab
- A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingPhase 2Jin YingNCT06483282Written as Adebrelimab
- Perioperative Adebrelimab for Locally Advanced Cervical CancerNot yet recruitingPhase 2Anhui Provincial HospitalNCT07811375Written as Adebrelimab
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07679360Written as Adebrelimab Injection
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Written as Adebrelimab
- Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingPhase 2First Affiliated Hospital Xi'an Jiaotong UniversityNCT07796113Written as Adebrelimab + Famitinib + Chemotherapy
See all 180 studies that test adebrelimab →
Given in every arm · 44 — adebrelimab is usual care beside what is tested
- A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07136142Written as SHR-1316 Injection
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002Written as Adebrelimab Injection
- Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingPhase 2Fudan UniversityNCT07638852Written as Adebelimab
- Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary GlioblastomaNot yet recruitingPhase 2Wei JiangNCT07789379Written as Adebrelimab
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as Adebrelimab
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07682272Written as Adebrelimab Injection
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474455Written as SHR-1316 Injection
- Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCCNot yet recruitingPhase 2Chen ChunyanNCT07554768Written as Adebrelimab
- Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)RecruitingPhase 2Sichuan UniversityNCT06610734Written as Adebrelimab
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07266025Written as Adebrelimab
- A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid TumorsRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07268040Written as SHR-1316 Injection
- A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571Written as Adebrelimab Injection
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051Written as Adebrelimab Injection
- A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229586Written as SHR-1316 Injection
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid TumorsRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06703177Written as Adebrelimab Injection
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729Written as Adebrelimab
- Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07238569Written as Adebrelimab (PD-L1 inhibitor)
- Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07041437Written as Adebrelimab
- SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775Written as Adebelimab injection
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06963502Written as Adebrelimab
Showing 20 of 44.
As the comparator · 3 — what is tested is compared with adebrelimab
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingPhase 2Tan LijieNCT07770672Written as Adebrelimab Plus Chemotherapy
- Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung CancerNot yet recruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07560358Written as adebrelimab,Radiation Therapy,Radiotherapy
- Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical TrialNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06771154Written as Adebelimab
Codes
What other systems call adebrelimab · ClinicalTrials.gg INT014364
- UNII (FDA) 1XBY50W1OXADEBRELIMABOne source FDA
- NCI Thesaurus C148535AdebrelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1XBY50W1OX | ADEBRELIMAB | One source FDA |
| NCI Thesaurus | C148535 | Adebrelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.